在中医学“络病”理论指导下的专利处方芪蓟肾康汤是临床应用20余年的院内制剂——消斑愈肾颗粒优化后处方，其作用机制尚不清楚。在前期体外研究基础上，提出科学假说： IgA肾病发病机制可能与 TGF-β1/Smads和ERK信号转导密切相关；运用“补肾络、清肾络、消肾络”中药复方可能通过调控以上两条通路，而发挥治疗作用。研究以CS57BL/6J转基因小鼠为研究对象，以芪蓟肾康汤为研究因素，通过体内实验干预NF-kB、ERK、Smads和效应因子IL-6、MCP-1、TNF-α、TGF-β1蛋白、基因水平的表达，观察IgA肾病的作用靶点FN、Col-IV，阐明IgA肾病的发病机制及芪蓟肾康汤的疗效作用。研究将揭示“肾络病“理论的科学内涵，为中医药学拓展新的治疗途径。

Under the guidance of the“Collaterals Disease” theory, QiJiShenKang, a patent prescription drug, has been used clinically more than 20 years in our university- affiliated hospital. But until now, the mechanism of its function is still unclear. Based on the preliminary study in vitro, we hypothesized that IgA nephropathy pathogenesis may be a closely related with TGF-β1/Smads and the ERK signal transduction pathway. The traditional Chinese medicine(TCM) compounds prescription, could be nourish kidney collaterals, clear kidney collaterals and dispell kidney collaterals, play a therapeutic role by regulating TGF -β1/Smads and the ERK signal transduction pathway. Aim of this study is to identify the pathogenesis of IgA nephropathy and the therapeutic role of QiJiShenKang. Using CS57BL/6J genetically modified mice, were treated with QiJiShenKang prescription, to study the change of the targets FN, Col - IV of IgA nephropathy. And at the same time, to study the mRNA and protein expression levels of NF-κB, ERK, Smads , IL-6, MCP- 1, TNF-α, TGF-β1.This research will reveal the scientific significance of kidney collaterals disease, and develop new TCM therapy pathways.